Enzyme Replacement Therapy for Hypophosphatasia
Summary
Hypophosphatasia (HPP) is an inherited metabolic disorder characterised by deficient activity of tissue non-specific alkaline phosphatase (TNAP), leading to impaired bone and dental mineralisation. Accumulation of substrates such as inorganic pyrophosphate (PPi) inhibits hydroxyapatite deposition in the extracellular matrix, resulting in rickets, osteomalacia and premature tooth loss. Enzyme replacement therapy (ERT) aims to restore TNAP activity by administering recombinant, mineral-targeted enzyme to compensate for the genetic deficiency. Asfotase alfa, the first approved ERT, has demonstrated substantial improvements in skeletal mineralisation, motor function and quality of life across paediatric and adult HPP populations. Next-generation agents, including modified TNAP constructs, seek to optimise pharmacokinetics and reduce immunogenicity. The global deployment of ERT has transformed the clinical outlook for patients with severe HPP, underscoring the importance of early diagnosis, multidisciplinary management and long-term monitoring of efficacy and safety.
Research from Nature Portfolio
Recent structural studies have elucidated the octameric assembly of human TNAP, revealing how pathogenic mutations disrupt enzyme stability and function. High-resolution crystal and cryo-electron microscopy analyses identified a novel interface targeted by an agonist antibody that binds TNAP octamers, enhancing osteoblast mineralisation in vitro. These findings deepen understanding of TNAP molecular pathology and pave the way for antibody-based therapies or engineered TNAP variants that stabilise the enzyme in the extracellular milieu to improve clinical outcomes.
Enzyme Replacement Therapy for Hypophosphatasia publication trend
The graph below shows the total number of articles in enzyme replacement therapy for hypophosphatasia across all publications each year (not limited to Nature Index journals).
Technical terms
Tissue non-specific alkaline phosphatase (TNAP): A membrane-anchored enzyme essential for bone and tooth mineralisation by hydrolysing phosphate-containing substrates.
Asfotase alfa: A recombinant, mineral-targeted TNAP replacement therapy approved for paediatric and adult hypophosphatasia to restore extracellular enzyme activity.
Efzimfotase alfa: A second-generation TNAP enzyme replacement candidate with modified pharmacokinetic properties under clinical evaluation for improved dosing and tolerability.
Inorganic pyrophosphate (PPi): A natural TNAP substrate that inhibits hydroxyapatite formation when accumulated extracellularly, contributing to the hypomineralisation seen in HPP.
References
- The structural pathology for hypophosphatasia caused by malfunctional tissue non-specific alkaline phosphatase. Nature Communications (2023).
- Safety, pharmacokinetics, and pharmacodynamics of efzimfotase alfa, a second-generation enzyme replacement therapy: phase 1, dose-escalation study in adults with hypophosphatasia. Journal of Bone and Mineral Research (2024).
- Medical Management of Hypophosphatasia: Review of Data on Asfotase Alfa. Current Osteoporosis Reports (2025).
- Monitoring guidance for patients with hypophosphatasia treated with asfotase alfa. Molecular Genetics and Metabolism (2017).
- Alkaline Phosphatase and Hypophosphatasia. Calcified Tissue International (2015).
About these summaries
This Nature Research Intelligence Topic summary is created with the cited references and a large language model. We take care to ground generated text with facts, and have systems in place to gain human feedback on the overall quality of the process in line with our AI principles. We strive to create accurate and useful summaries for people unfamiliar with the research topic and that supports this goal. These pages are a beta release and will be updated as we learn how best to help people gain value from a research topic summary.
Turn complex research questions into confident strategic decisions
When you're under pressure to set direction, justify investment, or understand your competitive position, you need more than raw data — you need trusted insights you can act on.
Benchmark your performance against global peers using robust, methodologically sound analysis.
Combine quantitative metrics with qualitative expert insight to uncover strengths, gaps and emerging opportunities.
Gain tailored, decision-ready recommendations aligned to your strategic priorities.
Talk to us to learn more about our data dashboards and bespoke strategy reports.
Grow research skills, confidence and careers with training built for every stage of the research lifecycle.
Developed with Nature Portfolio journal Editors and internationally renowned experts. Discover three ways to learn:
Self-paced, online courses in convenient bite-sized units, covering key skills across scientific writing, publishing, grant writing, data analysis, and more.
Expert trainer-led workshops with hands-on exercises and real-time feedback across core research skills, delivered via interactive group sessions.
Editor-led workshops combining core principles in writing and publishing, personalised 1:1 feedback from Nature Portfolio Editors and hands-on exercises.
Explore course catalogues and workshop agendas, enquire about the options or request institutional pricing.